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Elevated bone mineral parameters have been associated with
mortality in dialysis patients. There are conflicting data about
calcium, parathyroid hormone (PTH), and mortality and few
data about changes in bone mineral parameters over time.
We conducted a prospective cohort study of 1007 incident
hemodialysis and peritoneal dialysis patients. We examined
longitudinal changes in bone mineral parameters and
whether their associations with mortality were independent
of time on dialysis, inflammation, and comorbidity. Serum
calcium, phosphate, and calcium–phosphate product (CaP)
increased in these patients between baseline and 6 months
(Po0.001) and then remained stable. Serum PTH decreased
over the first year (Po0.001). In Cox proportional hazards
models adjusting for inflammation, comorbidity, and other
confounders, the highest quartile of phosphate was
associated with a hazard ratio (HR) of 1.57 (1.07–2.30) using
both baseline and time-dependent values. The highest
quartiles of calcium, CaP, and PTH were associated with
mortality in time-dependent models but not in those using
baseline values. The lowest quartile of PTH was associated
with an HR of 0.65 (0.44–0.98) in the time-dependent model
with 6-month lag analysis. We conclude that high levels of
phosphate both at baseline and over follow-up are
associated with mortality in incident dialysis patients. High
levels of calcium, CaP, and PTH are associated with mortality
immediately preceding an event. Promising new
interventions need to be rigorously tested in clinical trials for
their ability to achieve normalization of bone mineral
parameters and reduce deaths of dialysis patients.
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Patients with end-stage renal disease are at higher risk for
mortality than the general population.1 The primary cause of
death in end-stage renal disease is cardiovascular disease
(CVD). Patients with end-stage renal disease have many of
the same risk factors for mortality as the general population,
but the higher risk seen in dialysis patients cannot be fully
explained by prevalence of traditional risk factors.2 Novel risk
factors for mortality, including anemia and abnormal
calcium and phosphate metabolism,3 have been proposed
to explain this greater risk of CVD.
High levels of serum calcium, phosphate, calcium–pho-
sphate product (CaP), and parathyroid hormone (PTH) have
been shown to be associated with all-cause and cardiovas-
cular-specific mortality in persons with kidney disease.4–8 In
contrast, other studies have shown that low PTH and calcium
levels are associated with mortality9,10 or no association at
all.11 These conflicting results may be due to use of secondary
databases, prevalent patients, and single measures of calcium,
phosphate, and PTH. Importantly, there have been few data
on prospective changes in bone mineral metabolic para-
meters; therefore, use of a single value has not been validated.
If prospective changes exist in bone mineral parameters, this
may explain some of the previous conflicting results using a
single measure in patients with different dialysis durations.
Despite limitations in prior epidemiologic studies, several
therapeutic agents have been developed and are increasingly
used based on the assumption that the described relation-
ships are causal in nature and that optimization of bone
mineral metabolic parameters will lead to improvement in
outcome and patient survival. No clinical trial to date proves
this hypothesis. We therefore tested the hypothesis that
abnormal bone mineral parameters are associated with
mortality in a large prospectively collected national cohort
of incident dialysis patients with repeated measures of
laboratory values, detailed information on a variety of
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important confounders, and validated outcomes in order to
quantitate these relationships more precisely and to examine
whether associations are truly independent of potential
confounders, such as inflammation. Such information is
essential to facilitate the appropriate study and use of the new
interventions that target bone mineral parameters.
RESULTS
Patient characteristics
Our sample included 746 hemodialysis patients and 259
peritoneal dialysis patients from the CHOICE (Choices for
Healthy Outcomes in Caring for End-Stage Renal Disease
(ESRD)) (Table 1). Patients were followed for a median of 2.5
(intraquartile range 1.3–4.3) years with 460 deaths occurring
during follow-up. Patients in the highest calcium quartile
were more likely to be female, have a hemoglobin 410.8 g/dl,
be non-African American and were less likely to have PTH
4160 pg/ml relative to patients in lower quartiles. Patients in
the highest quartile of serum phosphate compared to the
other quartiles were less likely to be 465 years old, African
American, or to have been referred to a nephrologist o4
months prior to initiating dialysis but were more likely to
have smoked. The highest quartile of PTH had a greater
percentage of patients who were African American, high
school graduates, employed, had a body mass index
(BMI)425 kg/m2, had an albumin 43.7 g/dl, and were on
injectable vitamin D therapy at baseline, but had fewer
patients with a hemoglobin 410.8 g/dl, with diabetes
mellitus and who were referred to a nephrologisto4 months
prior to initiation of dialysis. Phosphate explained 91% of the
variance of CaP at baseline. Trends in CaP mirrored those of
phosphate alone (data not shown), except that patients with
higher BMIs tended to have higher CaPs and late referral to a
nephrologist was not significantly associated with CaP.
Longitudinal changes in bone mineral parameters
Mean serum calcium, phosphate, and CaP significantly
increased between the baseline period and the 6-month
period: calcium, from 9.35 to 9.51 mg/dl (Po0.001);
phosphate, from 5.23 to 5.43 mg/dl (Po0.001); and CaP,
from 48.9 to 51.7 mg2/dl2 (Po0.001 for all). After 6 months
of follow-up, mean serum calcium, phosphate, and CaP
remained stable (Figure 1). Serum PTH levels fell after the
initiation of dialysis and continued to fall for the next year.
Median serum PTH then increased reaching a new plateau at
around 2 years (Figure 1). Using generalized estimating
equations modeling to assess the association of bone mineral
parameters with increasing Index of Coexistent Disease
(ICED) score, we found that per 1-unit increase in ICED
score, calcium increased 0.07 mg/dl (0.03–0.10) (P¼ 0.001),
phosphate increased 0.09 mg/dl (0.01–0.17) (P¼ 0.03), CaP
increased 1.10 mg2/dl2 (0.31–1.88) (P¼ 0.006), and PTH
decreased by 14.6 pg/ml (34.4 to 5.16) (P¼ 0.15).
Association between serum calcium and all-cause mortality
Table 2 shows the association between serum calcium
quartiles and mortality adjusted for potential confounders,
using baseline, time-dependent, and time-dependent with lag
models. The highest quartile of serum calcium was
significantly associated with mortality in time-dependent
Table 1 | Patient characteristics at baseline, stratified by serum calcium, phosphate, and PTH quartiles
Serum calcium quartile (mg/dl) Serum phosphate quartile (mg/dl) Serum PTH quartile (pg/ml)
Characteristic (n)
All
patients
(1007) (%)
o8.97
(251) (%)
8.97–9.33
(254) (%)
9.33–9.73
(250) (%)
49.73
(252)
(%)
o4.3
(248)
(%)
4.3–5.1
(260) (%)
5.1–6
(243) %
46
(259) %
o76
(166) %
76–160
(167) (%)
160–308
(165) (%)
4308
(168)
(%)
Age 465 years 36 37 35 38 35 47 44 32 24 38 38 40 30
Female 46 38 43 44 59 50 48 44 43 51 41 40 49
African American 28 24 32 32 21 31 31 26 23 18 17 33 41
Hemodialysis 74 68 76 79 74 67 73 80 77 83 84 81 83
Ever smoked 61 61 64 58 60 54 61 60 67 62 58 65 53
Baseline CVD 57 56 63 59 52 60 59 58 53 60 62 58 54
Diabetes mellitus 55 55 60 55 49 53 52 56 58 56 62 63 45
ICED 2 34 33 31 35 39 34 32 31 41 37 37 32 32
ICED 3 30 27 32 33 28 31 32 34 23 36 28 32 29
Late referral o4 months
(805)
30 26 30 34 30 32 36 30 22 38 31 27 19
High school grade (944) 70 68 72 68 73 66 70 70 74 68 79 64 74
Employed 13 17 13 8 14 10 14 12 17 10 11 12 20
BMI 425 kg/m2 59 62 58 59 55 53 56 64 61 51 52 67 67
Calcitriol use 40 44 44 38 34 42 41 39 39 31 41 50 55
CRP 40.4 (844) 48 47 46 48 49 50 50 46 45 51 45 45 45
IL-6 46.0 (844) 51 47 53 52 50 52 54 49 47 52 47 51 47
Alb 43.7 48 46 47 49 48 45 47 44 55 39 49 49 55
Hgb 410.8 51 43 52 48 60 53 55 47 48 52 56 49 40
PTH 4160 (666) 50 75 57 46 23 43 49 52 56
Alb, albumin (g/dl); BMI: body mass index; CRP, C-reactive protein (mg/dl); CVD, cardiovascular disease; Hgb, hemoglobin (g/dl); ICED, Index of Coexistent Disease; IL-6,
interleukin-6 (pg/ml); PTH, parathyroid hormone (pg/ml),
Boldface values represent Po0.05.
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analysis, but not when using baseline and time-dependent
with lag analyses. The time-dependent model showed that
having a calcium 49.73 mg/dl was associated with a 52%
increased risk of death, compared to the reference range
(8.97–9.33 mg/dl).
Association between serum phosphate and all-cause mor-
tality
The relationship between serum phosphate and mortality is
shown in Table 2. The highest quartile of phosphate
(46.0 mg/dl) was associated with a higher mortality in the
baseline and time-dependent models, with a 57% higher risk
of death for the highest quartile compared with the reference
quartile (4.3–5.1 mg/dl) in the time-dependent model. In the
time-dependent model with lag, the third phosphate quartile
(5.1–6.0 mg/dl) was associated with an 83% higher mortality
risk than the reference quartile.
Association between serum calcium–phosphate product and
all-cause mortality
In the baseline and time-dependent with lag models, there
was no association between CaP and mortality (Table 2).
However, using time-dependent CaP values, the highest
quartile of CaP (456.4 mg2/dl2) was associated with an 87%
higher risk of mortality compared to the reference quartile
(40.2–47.7 mg2/dl2).
Association between parathyroid hormone and all-cause
mortality
There was no association between baseline PTH values and
mortality (Table 2). In the time-dependent with lag analysis,
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Figure 1 | Mean serum calcium, phosphate, CaP product, and
median serum PTH values over the first 36 months after
initiation of dialysis.
Table 2 | Associations of serum calcium, phosphate, CaP, and PTH at different time points with all-cause mortality
Baseline values as predictors
(n=552)
Time-dependent predictors with
6-month lag (n=578)
Time-dependent predictors
(n=593)
Serum calcium (mg/dl) quartile: level
o8.97 0.92 (0.60–1.39) 0.91 (0.58–1.43) 1.31 (0.83–2.05)
8.97–9.33 1.0 (reference) 1.0 (reference) 1.0 (reference)
9.33–9.73 1.13 (0.78–1.64) 1.17 (0.76–1.80) 1.33 (0.85–2.07)
49.73 1.05 (0.69–1.62) 1.37 (0.93–2.02) 1.52 (1.02–2.26)*
Serum phosphate (mg/dl) quartile:
level
o4.3 1.04 (0.70–1.53) 1.36 (0.89–2.06) 1.10 (0.74–1.64)
4.3–5.1 1.0 (reference) 1.0 (reference) 1.0 (reference)
5.1–6.0 1.01 (0.69–1.47) 1.83 (1.20–2.79)** 1.08 (0.70–1.67)
46.0 1.54 (1.01–2.35)* 1.41 (0.93–2.13) 1.57 (1.07–2.30)*
Serum CaP (mg2/dl2) quartile: level
o40.2 0.94 (0.64–1.39) 1.11 (0.73–1.68) 1.30 (0.85–1.98)
40.2–47.7 1.0 (reference) 1.0 (reference) 1.0 (reference)
47.7–56.4 1.03 (0.71–1.49) 1.37 (0.90–2.07) 1.50 (0.98–2.31)
456.4 1.35 (0.89–2.05) 1.28 (0.86–1.89) 1.87 (1.25–2.80)**
Serum PTH (pg/ml) quartile: level
o76 0.77 (0.51–1.19) 0.65 (0.44–0.98)* 0.86 (0.55–1.33)
76–160 1.03 (0.68–1.55) 0.67 (0.43–1.04) 1.01 (0.64–1.59)
160–308 1.0 (reference) 1.0 (reference) 1.0 (reference)
4308 0.84 (0.55–1.28) 1.23 (0.76–1.98) 1.68 (1.01–2.78)*
No vitamin D medication use 1.0 (reference) 1.0 (reference) 1.0 (reference)
Vitamin D medication use 0.62 (0.44–0.86)* 0.73 (0.54–0.98)* 0.74 (0.56–1.00)*
CaP, calcium–phosphate product; PTH, parathyroid hormone.
*Po0.05; **Po0.01.
Models adjusted for age, sex, race, baseline modality, smoking (ever vs. never), body mass index, Index of Coexistent Disease category, baseline diabetes mellitus, baseline
cardiovascular disease, log baseline interleukin-6, log baseline C-reactive protein, time-dependent albumin, time-dependent hemoglobin, education, employment status, late
referral, and vitamin D medication use (only in non-baseline models). Calcium, phosphate, and CaP models adjusted for PTH. PTH model adjusted for calcium and phosphate.
Vitamin D medication use adjusted for calcium, phosphate, and PTH.
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there was no association between an elevated PTH and
mortality; however, having a PTHo76 pg/ml was associated
with approximately a 35% lower risk of mortality. In the
time-dependent analysis, the highest quartile of PTH
(4308 pg/ml) was associated with a 68% greater risk of
mortality compared to the reference quartile (160–308 pg/
ml).
Association between injectable calcitriol and all-cause mor-
tality
Patients who received injectable vitamin D in the population
had a 26% lower mortality compared to those who did not
receive vitamin D (Table 2); this association of injectable
vitamin D treatment with reduced mortality was seen in all
statistical models.
Six-month changes in calcium, phosphate, and calcium–pho-
sphate product and all-cause mortality
Patients who had increasing levels of calcium had a 76%
higher mortality risk than those with low/normal levels at
both time points (Table 3). Having serum phosphate levels
decrease from baseline to 6 months was associated with a
72% higher mortality compared to those who had low/
normal levels at both time points. In a sensitivity analysis
excluding patients with a serum phosphate o3.5 mg/dl,
having serum phosphate levels decrease from baseline to 6
months was associated with a hazard ratio of 1.82
(1.12–2.98).
Subgroup analysis
Subgroup analyses using time-dependent models revealed no
differences in the above relationships between hemodialysis
and peritoneal dialysis patients or patients with and without
diabetes mellitus (Table 4). Although the p-interactions were
not significant between different dialysis modalities, the
peritoneal dialysis subgroup was too small to allow for valid
multivariate analysis. In the time-dependent models, adding
non-adherence or Kt/V as adjusters did not change the
association between elevated serum phosphate and mortality;
the highest quartile of phosphate (46.0 mg/dl) had a hazard
ratio of 1.67 (1.08–2.59) adjusting for non-adherence, and
1.63 (1.01–2.62) adjusting for Kt/V.
DISCUSSION
There have been no clinical trials showing that normalization
of bone mineral parameters decreases mortality; the next best
study to evaluate these associations is a prospective cohort
study, such as the CHOICE Study, which is able to take into
account changes in bone mineral parameters over time. The
results from this nationally representative dialysis cohort
study show that levels of mean serum calcium, phosphate,
and CaP increased from baseline to 6 months and then
remained stable. Serum calcium is low in patients with
chronic kidney disease, and upon initiating dialysis, patients
commonly receive vitamin D replacement therapy, calcium-
based phosphate binders, and calcium in dialysate fluid.
Therefore, serum calcium levels would be expected to
increase after initiation of dialysis. However, we found that
serum phosphate levels increased during this time period as
well and that increasing levels of comorbidity were associated
with increasing levels of calcium and phosphate. Block et al.,5
in their analysis of a prevalent population, also found that
higher levels of phosphate were found in patients who had
been on dialysis for a longer time period. Serum phosphate
levels rebound after dialysis treatment,12 and vitamin D
medications, such as calcitriol, can increase patients’ serum
phosphate by increasing its intestinal absorption. Another
factor contributing to the increasing phosphate level over
time could be loss of residual renal function.
The relationship between serum calcium and mortality
remains unclear. In the Dialysis Morbidity and Mortality
Study Wave 1, Block et al.4 showed no relationship between
levels of serum calcium and mortality after adjustment for
serum albumin. Foley et al.10 reported an increased mortality
in patients with a low serum calcium level (o8.8 mg/dl).
Block et al.,5 in a larger study, suggested that there is a graded
association between higher serum calcium and higher
mortality risk. In this analysis, high levels of serum calcium
were associated with mortality only in time-dependent
models, but not in baseline or lagged time-dependent
models. Also, as mentioned above, we saw that increasing
calcium levels were associated with increasing comorbidity.
In this study, we were able to show that serum phosphate
had an association with mortality that was independent of
inflammation, comorbidity, and non-adherence and robust
Table 3 | Relative risk of all-cause mortality in patients surviving 6 months by change in the level of serum calcium, serum
phosphate, and CaP
Serum calcium 9.73 mg/dl Serum phosphate 6.0 mg/dl Serum CaP 56 mg2/dl2
Levels at baseline and 6 months N Relative risk (95% CI) N Relative risk (95% CI) N Relative risk (95% CI)
Low/normal 498 1.0 (reference) 538 1.0 (reference) 509 1.0 (reference)
Increase 185 1.76** (1.23–2.51) 148 0.92 (0.63–1.35) 154 1.14 (0.78–1.67)
Decrease 85 1.32 (0.83–2.09) 103 1.72* (1.06–2.79) 90 1.60 (0.97–2.62)
High 133 1.19 (0.74–1.90) 118 1.36 (0.84–2.21) 146 1.33 (0.86–2.04)
CaP, calcium–phosphate product; CI, confidence interval.[2]*Po0.05; **Po0.01.
All models adjusted for age, sex, race, baseline modality, smoking (ever vs never), body mass index, Index of Coexistent Disease category, diabetes mellitus, baseline
cardiovascular disease, log interleukin-6, log C-reactive protein, time-dependent albumin and hemoglobin and education, vitamin D medication status, employment status,
and late referral. Calcium, phosphate, and CaP models adjusted for parathyroid hormone.
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in several different statistical models. While there have been
no clinical trials evaluating decreasing phosphate levels and
mortality, The Treat to Goal study showed less progression in
aortic calcification in patients treated with sevelamer
compared to calcium-based binders but did not evaluate
differences in mortality.13 In a secondary analysis, we found
that patients whose phosphate levels were high at baseline but
subsequently decreased significantly by 6 months had a
higher mortality relative to those whose levels were low at
both time points. Eliminating those with very low serum
phosphate (o3.5 mg/dl) did not change this finding. The
underlying mechanism is not clear but may involve poor oral
intake and/or the aggressive use of calcium-based phosphate
binders, which may both decrease the phosphate and increase
the calcium, both of which were found to be associated with
increased mortality in our analysis. We did not have
information on oral medications and therefore could not
account for their use in our analysis. Further studies are
needed to clarify these associations.
Laboratory and clinical studies have revealed possible
biological mechanisms to explain the relationship between
bone mineral parameters and mortality. High serum
phosphate level can differentiate vascular smooth muscle
cells into cells with osteoblastic activity, thereby promoting
mineralization of the vascular system.14,15 Higher calcium
intake is also associated with increased coronary calcification
in young hemodialysis patients.16 Raggi et al.17 similarly
showed an association between higher serum calcium and
phosphate levels and coronary calcification in a larger
population, as well as cross-sectional association of calcifica-
tions with myocardial infarction, angina, and claudication.
Calcification has been associated with increased arterial
stiffness and mortality.18,19
PTH can induce cardiomyocyte hypertrophy in vitro, and,
in a population-based study in Norway, epidemiological
evidence linked higher levels of PTH to left ventricular
hypertrophy.20,21 We found that the highest quartile of PTH
in the time-dependent analysis was associated with a 70%
elevated mortality risk compared to a level of 160–308 pg/ml,
one of the highest risk estimates thus far reported.6,9
However, using baseline and lagged analyses, we did not
find an association between high PTH and mortality. We
found that PTH levels o76 pg/ml were associated with a
lower mortality risk compared to levels of 160–310 pg/ml in a
lagged analysis. These findings are not entirely consistent
with previous data regarding associations of altered PTH
levels and mortality or vascular calcification.9,22,23 Similar to
our findings, Kestenbaum et al.24 reported that post-
parathyroidectomy patients, presumably with lower PTH
levels, have a survival benefit compared to matched controls.
These inconsistencies may result from poor agreement of
different PTH assays used in different studies and possibly
from the smaller sample size used in this analysis.
In our analysis, patients who had received calcitriol had a
survival advantage over patients who did not use calcitriol.
This benefit was most pronounced in the baseline analysis
most likely owing to a survival bias; patients had to have
survived long enough on dialysis to have received calcitriol.
This survival advantage of patients treated with calcitriol and
other injectable vitamin D medications has been reported
previously.11
There are limitations to this study. It is essential to
emphasize that like all other studies of bone mineral
parameters and mortality published to date, this is an
observational study and therefore causality cannot be directly
inferred. The sample size in our study is smaller than in other
studies; however, we were able to obtain repeated measures of
calcium, phosphate, CaP, and PTH. Over the time course of
the study, clinical practice has changed, with the introduction
of non-calcium-containing phosphate binders and new
vitamin D analogs, which we and others have not accounted
for in the analysis. Finally, although we have information on
whether or not patients received calcitriol, we could not
quantify the dosage.
In summary, elevated phosphate was independently
associated with all-cause mortality in a nationally represen-
Table 4 | Baseline values and time-dependent associations with mortality in hemodialysis and peritoneal dialysis subgroups
and in patients with and without diabetes
Hemodialysis (482) Peritoneal dialysis (111) P- value* Diabetes mellitus (329) No diabetes mellitus (264) P- value*
Mean values at baseline by subgroup
Calcium 9.39 (0.63) 9.31 (0.73) 0.09 9.34 (0.65) 9.40 (0.67) 0.17
Phosphate 5.28 (1.30) 5.04 (1.38) 0.01 5.25 (1.32) 5.19 (1.34) 0.50
CaP 49.6 (12.6) 46.8 (12.3) 0.002 48.9 (12.2) 48.8 (13.0) 0.89
PTH 158 (77–311) 164 (74–299) 0.60 151 (77–267) 176 (74–391) 0.06
Time-dependent associations with mortality in the highest quartile
Calcium 1.60 (1.03–2.49) — 0.83 1.65 (0.95–2.86) 1.16 (0.56–2.42) 0.66
Phosphate 1.71 (1.11–2.64) — 0.32 2.14 (1.25–3.67) 0.84 (0.38–1.86) 0.10
CaP 2.08 (1.32–3.29) — 0.39 2.76 (1.58–4.83) 1.13 (0.48–2.64) 0.21
PTH 1.79 (1.01–3.17) — 0.78 1.85 (0.91–3.78) 2.04 (0.73–5.71) 0.42
CaP, calcium–phosphate product; PTH, parathyroid hormone.
Reported as means (s.d.) or median (intraquartile range). *P-values reported from t-tests and Wilcoxon rank-sum tests for comparisons between groups and from interaction
terms in time-dependent models, adjusted as in Table 2.
—, numbers too small to give valid estimate.
Kidney International (2006) 70, 351–357 355
ML Melamed et al.: Changes in mineral metabolism and mortality o r i g i n a l a r t i c l e
tative incident dialysis cohort, even after accounting for
measures of inflammation, education, employment, referral
time, and other confounders. Elevated calcium, CaP, and
PTH were associated with mortality only in time-dependent
models, suggesting that the association may be more complex
than previously understood. Our analysis also shows that
interventions used during the time of the study were
inadequate in lowering phosphate levels. This and other
observational studies suggest that clinicians need to target
serum phosphate aggressively to prevent death in end-stage
renal disease patients. Our analysis strengthens the potential
impact of NKF-KDOQI guidelines for normalization of bone
mineral parameters.25 The evident complexity of the
associations between bone mineral levels and survival
mandates that potential new interventions and enhanced
methods to implement them need to be rigorously tested in
appropriately sized clinical trials for their ability to achieve
normalization of bone mineral parameters and reduce deaths
of dialysis patients.
MATERIALS AND METHODS
Study design and research population
We conducted a national cohort study using a subcohort from the
CHOICE Study. CHOICE is a national, prospective cohort study
initiated to investigate treatment choices and outcomes of dialysis
care among patients initiating dialysis. From October 1995 to June
1998, 1041 (767 hemodialysis and 274 peritoneal dialysis) patients
were enrolled from 81 dialysis clinics in 19 states; enrollment
occurred a median of 45 days after the start of dialysis (98% within 4
months). These included clinics associated with Dialysis Clinic Inc.
(Nashville, TN, USA; n¼ 923), New Haven CAPD (New Haven, CT,
USA; n¼ 86), and St Raphael’s Hospital (New Haven, CT, USA;
n¼ 32). Patients enrolled in CHOICE were similar to patients
initiating dialysis in the United States in 1997 except that CHOICE
oversampled peritoneal dialysis patients to allow for compari-
sons.2,26 Entry criteria included the initiation of chronic outpatient
dialysis in the preceding 3 months, ability to provide informed
consent for participation, age older than 17 years, and ability to
speak English or Spanish. A specimen bank was established to store
blood samples from the Dialysis Clinic Inc. participants, and
specimens were obtained for 898 (97.3%) of the Dialysis Clinic Inc.
enrollees. Patients included in this analysis had to have serum
calcium and phosphate at baseline (n¼ 1007). The Johns Hopkins
University School of Medicine Institutional Review Board and the
review boards for the clinical centers approved the study protocol.
All patients gave written informed consent before participation in
the study.
Data collection
Dialysis modality at baseline was defined as the modality at 4 weeks
after enrollment in the study and was categorized as hemodialysis or
peritoneal dialysis. Data regarding patient demographics and
medical history were collected from a self-report questionnaire
and chart review. Baseline CVD was coded as positive if the patient
had a history of coronary artery disease, myocardial infarction,
cerebrovascular disease, peripheral vascular disease, or transient
ischemic attack at dialysis initiation. Patients were categorized as
non-adherent (yes/no) if they had missed 43% of their hemodia-
lysis sessions per month, after accounting for missed dialysis
secondary to hospitalization.27 No adherence data were available for
peritoneal dialysis patients. The degree of comorbidity was assessed
using the ICED, an instrument that has been validated in dialysis
populations.28,29 The ICED score ranges from 0 to 3 (with 3
indicating highest severity), and is calculated from two constituent
indices that were assessed at baseline and 12 months, the 19-axis
Index of Disease Severity and the 11-axis Index of Physical
Impairment.
Laboratory data included repeated measures of serum calcium,
phosphate, PTH, albumin, and hemoglobin. The baseline laboratory
parameters were those collected in the 3 months surrounding
enrollment in the study (45 days before and 45 days after
enrollment). PTH levels were measured using the Diasorin intact
PTH assay (Diasorin Inc., Stillwater, MN, USA). Serum calcium
levels reported in the study were adjusted for albumin using the
following formula: adjusted calcium¼measured cal-
cium((4.0serum albumin in g/dl) 0.8). High-sensitivity C-
reactive protein (CRP) and interleukin-6 (IL-6) were performed on
all patients with frozen serum available in the CHOICE specimen
bank (n¼ 844). Single-pool Kt/V at 6 months, calculated using
previously published methods,30 was available for hemodialysis
patients. Injectable vitamin D use data, available for calcitriol only,
were obtained from linked United States Renal Data System billing
data. Patients were categorized as having received or not received
injectable vitamin D (calcitriol) during follow-up. Mortality was
ascertained through communication with the dialysis clinics and
monthly reports from the central Dialysis Clinic Inc. database.
Statistical analysis
Characteristics of the population stratified by serum calcium,
phosphate, PTH, and CaP quartiles were compared using w2 tests for
categorical variables. CRP, IL-6, albumin, hemoglobin, and PTH
levels were categorized based on the median baseline value of the
population. Mean serum calcium, phosphate, and CaP levels at
baseline and 6 months were compared using paired Student’s t-tests.
PTH values were compared using the Wilcoxon rank-sum test. To
assess whether increasing comorbidity (ICED) is associated with
changes in bone mineral parameters, we used generalized estimating
equations to estimate the changes in bone mineral parameters from
baseline to 1 year associated with increased ICED from baseline to 1
year, adjusting for age, sex, and race.
We used Cox proportional hazards analysis to assess the
presence, strength, independence, and statistical significance of the
association of mean quarterly bone mineral levels with all-cause
mortality. The mean serum calcium, phosphate, CaP, PTH, albumin,
and hemoglobin levels using all available results for each quarter
were used as the exposure for each 3-month follow-up period. When
there were no available results for a given parameter within a specific
quarter (13% in the first year, 16% in the second year for calcium
and phosphate), values were assigned using the last observation
carried forward method. To examine the influence that secular
trends in bone mineral levels might have on mortality, we ran
separate analyses using baseline values only (3 months surrounding
enrollment), using updated values of bone mineral parameters in a
time-dependent fashion, and using time-dependent values with a 6-
month lag (i.e. allowing bone mineral parameter to change with
time only up to 6 months before the event). Adjustment was
performed using the potential confounders age, race, sex, diabetes
status, baseline modality, baseline CVD, ICED, referral time to a
nephrologist, education, employment, time-dependent albumin,
time-dependent hemoglobin, CRP, IL-6, vitamin D medication use,
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and the remaining bone mineral parameters: PTH for the calcium,
phosphate, and CaP models and serum calcium and phosphate for
the PTH models. For the baseline values models, vitamin D
medication use was not included in the model because patients had
to have survived to use vitamin D, thereby introducing a survival
bias to the estimates. All analyses were stratified by dialysis clinic to
account for intraclinic practice variation. Patients were censored at
transplantation, transfer to another dialysis clinic, or last date of
follow-up (November 30, 2004).
Values of mineral parameters were categorized according to
quartiles of the baseline distribution. Quartile 2 was used as the
reference category for analyses of serum calcium, phosphate, and
CaP because of previous data showing a possible J-shaped
association with mortality.5,10 Quartile 3 was used as the reference
category for PTH because the cutoffs approximated the goal PTH
level under current guidelines.25 Subgroup analyses were performed
to evaluate whether there were differences in the association between
bone mineral parameters and mortality between hemodialysis and
peritoneal dialysis patients or between patients with and without
baseline diabetes mellitus, and sensitivity analysis was performed to
evaluate the separate effects of Kt/V and non-adherence.
To further examine individual changes in mineral parameters
over time, we looked at minerals separately using baseline and 6-
month patient-specific levels. A categorical variable was created
defining four groups of patients: those persistently below the 75th
percentile (low-normal; reference group), those persistently above
the 75th percentile at both time points (high), those that changed
from above to below the 75th percentile (decrease), and those that
changed from below to above the 75th percentile (increase). This
categorical variable was then used in the final model, as described
above. In a sensitivity analysis, we excluded patients with a serum
phosphate less than 3.5 mg/dl. Statistical analyses were performed
using Stata software, version 8.1 (Stata Corporation, College Station,
TX, USA).
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